• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. BDX

Becton, Dickinson and Company(BDX)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Instruments & Supplies
Becton, Dickinson and Company logo

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Latest News & Analysis

BDX Financial Analysis: Safety, Strategy, and Strong Cash Flow
Jun 5, 2025

BDX Financial Analysis: Safety, Strategy, and Strong Cash Flow

Explore Becton, Dickinson and Company's recent safety warning, strategic product initiatives, robust financial performance, and outlook amidst evolving healthcare industry dynamics in 2025.

Read more →
A professional illustration depicting strategic change and a potential Life Sciences divestiture at Becton Dickinson (BDX), alongside the launch of their AI-driven HemoSphere Alta medical technology platform.
Apr 21, 2025

BDX Strategic Shift: Analyzing Becton Dickinson's Portfolio and AI Innovation

Analyzing Becton Dickinson (BDX) at a pivotal moment: Potential Life Sciences divestiture, AI-driven HemoSphere Alta launch, Alaris recall impact, and dividend sustainability.

Read more →
BDX Stock Analysis: Divestiture, Recall, and Future Growth Prospects for Becton Dickinson. Insights for investors.
Apr 9, 2025

BDX's Strategic Overhaul: Life Sciences Divestiture, Alaris Recall

Becton Dickinson (BDX) is undergoing a strategic overhaul, considering the divestiture of its Life Sciences unit, addressing the Alaris infusion pump recall, and pursuing future growth opportunities.

Read more →
BDX strategic shift: Analyzing financial implications of life sciences unit divestiture, Alaris recall, and innovation recognition. Becton Dickinson stock analysis.
Apr 2, 2025

Becton Dickinson (BDX): Divestiture, Innovation, and Market Challenges

Becton Dickinson (BDX) navigates strategic shifts, innovation recognition, and challenges from an Alaris recall, impacting market valuation and growth opportunities.

Read more →
Becton Dickinson (BDX) stock analysis: GalaFLEX LITE trial, dividend performance, and future growth prospects. Medical technology investment insights.
Mar 25, 2025

Becton Dickinson (BDX): GalaFLEX Milestone, Dividend King Status, and Growth Outlook

Becton Dickinson (BDX) navigates growth via GalaFLEX LITE trial, strategic business separation, and commitment to dividend payouts, appealing to long-term investors.

Read more →
Becton Dickinson (BDX) stock analysis: Growth, innovation, and dividend stability in medical technology. Review of BDX's financial performance, clinical trials (GalaFLEX), and future prospects.
Mar 21, 2025

Becton Dickinson (BDX): Clinical Trials, Dividends, and Market Outlook

Becton Dickinson (BDX) navigates growth with clinical trials, dividends, and strategic acquisitions. A detailed analysis of financial health and market outlook.

Read more →
Becton Dickinson (BDX) stock analysis: strategic shift, Q1 2025 results, dividend aristocrat status, and investment outlook.
Mar 18, 2025

Becton Dickinson (BDX): Q1 2025 Results and Strategic Outlook

Becton Dickinson (BDX) navigates strategic shifts, strong Q1 results, and market dynamics. A deep dive into growth drivers, financial health, and future outlook.

Read more →
Becton Dickinson strategic shift: business separation, financial performance, and market dynamics analysis.
Feb 25, 2025

Becton Dickinson (BDX) Strategic Shift: Business Separation, Financials, and Market Analysis

Becton Dickinson (BDX) navigates a strategic shift with its business separation, strong financials, and a growing molecular diagnostics market. Starboard Value's influence adds another layer to this dynamic period.

Read more →
Becton Dickinson strategic separation, earnings, and market analysis. Insights into BDX's Biosciences and Diagnostic Solutions split and its future outlook.
Feb 24, 2025

Becton Dickinson (BDX): Strategic Separation, Earnings Analysis

Becton Dickinson (BDX) is strategically separating its business. Q1 2025 earnings beat expectations, but challenges remain in a competitive market.

Read more →
BDX strategic separation: Insights on growth, Q1 2025 performance, and molecular diagnostics market impact.
Feb 21, 2025

BDX Strategic Shift: Biosciences Separation & Market Outlook

In-depth analysis of BDX's strategic separation, robust Q1 earnings, and evolving dynamics in molecular diagnostics.

Read more →
Becton Dickinson Biosciences strategic separation: Market analysis, Q1 2025 earnings, and future outlook. Explore BDX's impact on MedTech and diagnostics.
Feb 21, 2025

Becton Dickinson Biosciences Separation: Strategy and Market Impact

Becton Dickinson navigates strategic shifts with a Biosciences separation, Q1 earnings beat, and evolving market dynamics. A data-driven intraday snapshot.

Read more →
Becton Dickinson strategic shift and molecular diagnostics market growth.
Feb 20, 2025

Becton, Dickinson and Company Announces Major Business Developments | Latest Industry News

Becton, Dickinson and Company navigates strategic shifts amid market growth, focusing on business separation and molecular diagnostics. A comprehensive intraday update.

Read more →
Becton Dickinson (BDX) company logo.
Feb 18, 2025

Becton Dickinson Navigates Strategic Shift: Analyzing Biosciences Separation and Market Outlook

BDX’s strategic separation and robust Q1 2025 earnings signal enhanced focus and growth potential in the MedTech sector.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.